

UCSF

UC San Francisco Previously Published Works

Title

Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop

Permalink

<https://escholarship.org/uc/item/16q2r5fm>

Journal

Human Immunology, 79(12)

ISSN

0198-8859

Authors

Misra, Maneesh K
Augusto, Danillo G
Martin, Gonzalo Montero
et al.

Publication Date

2018-12-01

DOI

10.1016/j.humimm.2018.10.003

Peer reviewed



Published in final edited form as:

Hum Immunol. 2018 December ; 79(12): 825–833. doi:10.1016/j.humimm.2018.10.003.

Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop

Maneesh K. Misra¹, Danilo G. Augusto^{1,2}, Gonzalo Montero Martin³, Neda Nemat-Gorgani⁴, Jürgen Sauter⁵, Jan A. Hofmann⁵, James A. Traherne⁶, Betsy González-Quezada⁷, Clara Gorodezky⁷, Will Bultitude⁸, Wesley Marin¹, Cynthia Vierra-Green⁹, Kirsten M. Anderson¹, Antonio Balas¹⁰, Jose L. Caro-Oleas¹¹, Elisa Cisneros¹², Francesco Colucci¹³, Ravi Dandekar¹, Sally Elfishawi¹⁴, Marcelo A. Fernández-Viña³, Merhan Fouda¹⁴, Rafael González-Fernández¹⁵, Arend Große¹⁶, Maria J. Herrero-Mata¹¹, Sam Q. Hollenbach¹⁷, Steven G. Marsh⁸, Alex Mentzer¹⁸, Derek Middleton¹⁹, Ashley Moffett²⁰, Miguel A. Moreno-Hidalgo¹⁰, Ghada Mossallam¹⁴, Annetee Nakimuli²¹, Jorge R. Oksenberg¹, Stephen J. Oppenheimer²², Peter Parham⁴, Maria-Luiza Petzl-Erler², Dolores Planelles²³, Florentino Sánchez-García²⁴, Francisco Sánchez-Gordo²⁵, Alexander H. Schmidt^{5,16}, John Trowsdale⁶, Luciana B. Vargas², Jose L. Vicario¹⁰, Carlos Vilches¹², Paul J. Norman^{#4,26}, and Jill A. Hollenbach^{#1}

¹Department of Neurology, University of California San Francisco, San Francisco, CA 94158, USA

²Department of Genetics, Universidade Federal do Paraná, Curitiba, Brazil ³Department of

Pathology, Stanford University School of Medicine, Stanford, CA 94304, USA ⁴Department of

Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA ⁵DKMS

gGmbH, Tübingen, Germany ⁶Department of Pathology, University of Cambridge, Cambridge, UK

⁷Department of Immunology and Immunogenetics, InDRE, Secretary of Health, Francisco P.

Miranda #177, Colonia Lomas de Plateros, Del. Álvaro Obregón, CP 01480; and, Fundación

Comparte Vida, A.C. Galileo #92, col. Polanco, Del. Miguel Hidalgo, CP 11550, Mexico City,

México. ⁸Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London NW3 2QG,

UK ⁹Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA

¹⁰Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain

¹¹Histocompatibility and Immunogenetics, Banc de Sang i Teixits, Barcelona, Spain

¹²Immunogenetics and Histocompatibility, Instituto de Investigación Sanitaria Puerta de Hierro,

Madrid, Spain ¹³Department of Obstetrics and Gynaecology, National Institute for Health

Research Cambridge Biomedical Research Centre, University of Cambridge School of Clinical

Medicine, Cambridge, UK and Centre for Trophoblast Research, University of Cambridge,

Cambridge, UK ¹⁴National Cancer Institute, Cairo University, Cairo, Egypt ¹⁵Immunology, Hospital

Universitario Reina Sofía, Córdoba, Spain ¹⁶DKMS Life Science Lab, Dresden, Germany

Corresponding author: Jill A. Hollenbach, Ph.D., M.P.H., Associate Professor, Department of Neurology, University of California San Francisco, San Francisco, CA 94158, USA, Phone: +1 415 502 7289, jill.hollenbach@ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹⁷Macalester College, St. Paul, MN 55105, USA ¹⁸Wellcome Trust Centre for Human Genetics, and Jenner Institute, University of Oxford, Oxford, UK ¹⁹Royal Liverpool University Hospital, Liverpool, L7 8XP, UK ²⁰Department of Pathology, University of Cambridge, Cambridge, UK and Centre for Trophoblast Research, Cambridge, UK ²¹Department of Obstetrics and Gynecology, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda ²²School of Anthropology and Museum Ethnography, University of Oxford, Oxford, UK ²³Histocompatibility, Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain ²⁴Immunology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain ²⁵Histocompatibility, Centro de Transfusión de Málaga, Málaga, Spain ²⁶Division of Biomedical Informatics and Personalized Medicine, and Department of Immunology, University of Colorado, Denver, CO 80045

These authors contributed equally to this work.

Abstract

The goals of the *KIR* component of the 17th International HLA and Immunogenetics Workshop (IHIW) were to encourage and educate researchers to begin analyzing *KIR* at allelic resolution, and to survey the nature and extent of *KIR* allelic diversity across human populations. To represent worldwide diversity, we analyzed 1269 individuals from ten populations, focusing on the most polymorphic *KIR* genes, which express receptors having three immunoglobulin (Ig)-like domains (*KIR3DL1/S1*, *KIR3DL2* and *KIR3DL3*). We identified 13 novel alleles of *KIR3DL1/S1*, 13 of *KIR3DL2* and 18 of *KIR3DL3*. Previously identified alleles, corresponding to 33 alleles of *KIR3DL1/S1*, 38 of *KIR3DL2*, and 43 of *KIR3DL3*, represented over 90% of the observed allele frequencies for these genes. In total we observed 37 *KIR3DL1/S1* allotypes, 40 for *KIR3DL2* and 44 for *KIR3DL3*. As *KIR* allotype diversity can affect NK cell function, this demonstrates potential for high functional diversity worldwide. Allelic variation further diversifies *KIR* haplotypes. We determined *KIR3DL3*~*KIR3DL1/S1*~*KIR3DL2* haplotypes from five of the studied populations, and observed multiple population-specific haplotypes in each. This included 234 distinct haplotypes in European Americans, 191 in Ugandans, 35 in Papuans, 95 in Egyptians and 86 in Spanish populations. For another 35 populations, encompassing 642,105 individuals we focused on *KIR3DL2* and identified another 375 novel alleles, with approximately half of them observed in more than one individual. The *KIR* allelic level data gathered from this project represents the most comprehensive summary of global *KIR* allelic diversity to date, and continued analysis will improve understanding of *KIR* allelic polymorphism in global populations. Further, the wealth of new data gathered in the course of this workshop component highlights the value of collaborative, community-based efforts in immunogenetics research, exemplified by the IHIW.

Keywords

KIR3DL1/S1; KIR3DL2; KIR3DL3

Introduction

The *Killer-cell Immunoglobulin-like Receptor (KIR)* region is located on human chromosome 19q13.4 [1–4]. KIR molecules are primarily expressed on natural killer (NK) cells [5] and a small percentage of T-cells [6]. KIR interact with specific amino acid motifs expressed by some human leukocyte antigen (HLA) class I molecules [5], and function to modulate the cytolysis of infected and/or otherwise altered cells, such as neoplastic cells. The *KIR* gene complex is characterized by structural variation that creates multiple gene-content haplotypes. In addition, each of the *KIR* genes exhibits allelic variability [7], which generates considerable intra- and inter-population diversity [8]. This diversity can influence immune responses against pathogens, which has the potential to alter the fitness of individuals [9, 10]. Specific combinations of KIR with their cognate HLA ligands are associated with autoimmunity [3, 11, 12], infectious diseases [13, 14], cancer [15, 16], pregnancy outcomes [17, 18], are crucial in determining clinical outcomes of hematopoietic stem cell transplantation (HCT), and solid organ transplants [19–22].

The allelefrequencies.net database (AFND) has collected *KIR* datasets from 245 populations across the globe [23]. A similar resource was recently developed called the KIR and Disease Database (KDDB), which gathered KIR associations from 204 published articles, and indicates a growing interest in *KIR* in epidemiological studies. These associations consisted of 32 autoimmune diseases, 19 infectious diseases, 16 cancer, eight chronic inflammatory diseases, three related to pregnancy, and one psychiatric disease. [24]. The complex polymorphism observed in this gene family, when combined with the high sequence similarity among *KIR* genes [25, 26], imposes technical difficulties for sequencing and genotyping to full allelic resolution. Thus, despite the fact that *KIR* gene content polymorphism has been extensively studied, *KIR* allelic diversity has been characterized in only a handful of well-defined populations [27–32].

KIR gene content variation was examined during previous International HLA and Immunogenetics Workshop (IHIW) studies. In the 15th and 16th IHIW, the *KIR* anthropology component (Population Global Distribution of KIR and Ligand) aimed to accumulate and examine the *KIR* and *HLA* frequencies in individuals recruited from distinct populations worldwide [33, 34], in order to replicate the earlier findings of coevolution of *KIR* and *HLA* [30, 33, 35, 36]. The preliminary studies conducted by Hiby et al. (2004) while investigating the role of maternal KIR and fetal HLA-C in preeclampsia, first raised the question whether KIR and HLA class I coevolution is related to reproductive fitness [17]. Single et al. (2007) demonstrated evidence of *KIR-HLA* coevolution, by showing a negative correlation of the frequency of *KIR3DS1* with *HLA-Bw4* [35], followed by several other studies corroborating the coevolution of *KIR* with *HLA* [30, 33, 36]. Further evidence of *KIR-HLA* coevolution was demonstrated in the 16th IHIW, in which 105 populations were examined and a strong positive correlation of KIR2DL3 and its ligand HLA-C1 was observed [34].

The goal of the 17th IHIW *KIR* component was to collect *KIR* allelic data to characterize the nature and extent of allelic diversity across human populations using primarily next generation sequencing (NGS) technology. As NGS for *KIR* has not yet been implemented in

several laboratories that study *KIR*, Sanger sequencing was also welcomed [30, 37]. All the participants performing *KIR* genotyping were required to validate their method by genotyping a control panel, however, the reference laboratories performed most genotyping. Many investigators participated in the *KIR* component by providing DNA specimens sequenced by one of the reference laboratories. Here, we present a summary of the *KIR* component of the 17th IHIW working group meeting, and the *KIR* allelic data generated from the 45 worldwide populations that were analyzed. Our preliminary analysis focused on the *KIR* genes that encode three Ig domain receptors because they have been most extensively characterized to the allelic level and their diversity has been shaped by natural selection [38].

Materials and methods

Participants from eleven laboratories submitted *KIR* allelic genotyping data from a total of 45 populations. Five populations were analyzed through the entire coding sequence for *KIR3DL1/S1*, *KIR3DL2* and *KIR3DL3* polymorphism, four for *KIR3DL2* and one for *KIR3DL1/S1*. Exons 4 and 5 from *KIR3DL2* were analyzed in the remaining 35 populations. The participants either used NGS platforms or Sanger sequencing to generate *KIR* allelic data locally, or contributed DNA samples to be sequenced at the workshop reference laboratory at Stanford University. The list of all populations, including sample size, *KIR* genes, sequencing method, sample contributor and the location where sequencing was performed is given in Table 1. Additionally, Single molecule real-time (SMRT) *KIR* gene sequencing was performed for 19 IHIW cell lines from populations including European, black southern African, Warao Amerindian and Chinese.

NGS genotyping of *KIR* genes containing three Ig-like domains

To determine the sequences of *KIR* genes containing three Ig-like domains, a previously described capture/enrichment method, followed by NGS [39] was applied. DNA isolated from healthy unrelated blood donors from the following populations was used: Ugandan (n = 174); Egyptian (n = 136); European American (USA) (n = 376); Papuan (n = 185); and Spanish (n = 153). The Ugandan, Egyptian and Spanish populations have been previously examined for *KIR* gene content [40–42]. Similarly, the European American sample was described in a recent *HLA* study [43]. The Papuan sample consists of individuals from both the highland and lowland regions, as described [44].

Sanger sequencing for genotyping *KIR3DL1/S1* and *KIR3DL2*

KIR3DL2 was genotyped using sequence-based typing in samples from Brazil, which included Euro-descendants from Curitiba (n = 42), non-mixed Brazilians with Japanese ancestry (n = 22) and Amerindians from the Kaingang (n = 30) and Guarani (n = 49) populations. The Brazilian populations have been previously described for *KIR* gene-content [45–47]. Exons 3, 4, 5, 7–9 were amplified with gene-specific primers and the products were sequenced with Big Dye terminator kit (Applied Biosystems) according to the manufacturer's instructions. Specific PCR-SSP primers were designed to resolve two common ambiguities; where it was otherwise not possible to distinguish the genotype *KIR3DL2**002+*010 from *KIR3DL2**010+*015, and the genotype *KIR3DL2**001+*007

from *KIR3DL2*006+*010*. Primer sequences are available upon request. *KIR3DL1/S1* was genotyped using sequence-based typing as reported earlier [30] in unrelated healthy Mexican Mestizos (n = 59). The Mexican Mestizos population *KIR* gene-content variation was examined in an earlier report [37].

Large scale *KIR3DL2* sequencing

Sequence data for exons 4 and 5 of *KIR3DL2* was generated from a total of 642,105 individuals from 35 populations (Table 1). PCR amplicons were generated from these exons individually, and then sequenced using Illumina paired-end technology (HiSeq or MiSeq). Alleles were called using the neXtype algorithm [48] and IPD-KIR library version 2.7.0 (Release, 14th July 2017) as the reference [7].

SMRT *KIR* gene sequencing for IHIW cell lines

In addition to the populations described above, *KIR* allele sequences were also generated for a small panel of IHIW cell lines. Briefly, samples underwent PCR targeting individual *KIR* genes to amplify full-length alleles (5' UTR to 3' UTR). Amplicons of the same locus were pooled together and sequenced on Pacific Biosciences' RSII platform using a movie time of six hours to obtain maximum read depth. A combination of Pacific Biosciences' SMRTAnalysis and Anthony Nolan's AlleleTeaSet software (Anthony Nolan Research Institute, London, UK) were used to demultiplex and analyze the sequences. For the purposes of this study, the coding domain sequences were extracted from the phased, full-length sequence for further analysis.

Data analysis

All data analysis including allele counts, and frequency estimations were performed in the R environment for statistical computing and visualization [49]. The haplotype analysis was carried out using the R 'haplo.stats' package [50].

The *KIR* Component Meeting

The *KIR* component meeting of the 17th IHIW was held during two breakout sessions. Each participant presented the results of the population data submitted by their group. Additionally, updates on the state of *KIR* haplotype reference sequences, *KIR* in Allele frequencies.net database, *KIR* nomenclature, and the IPD-KIR database were presented. Finally, there was an overview of PING (Pushing Immunogenetics to the Next Generation) software package [39], which is a bioinformatics pipeline for the analysis of next-generation sequencing *KIR* data. A supplementary file describes the schedule of the *KIR* component meeting, titles of the presentation and details of the presenters (Supplementary File S1).

Results

Allelic diversity of *KIR3DL1/S1*, *KIR3DL2* and *KIR3DL3*

We analyzed *KIR3DL1/S1*, *KIR3DL2* and *KIR3DL3*, which encode receptors having three Ig domains. These genes have been the most extensively characterized to date, and their

allelic diversity has been shown to be shaped by natural selection [38]. We observed 33 previously identified alleles of *KIR3DL1/S1*, 38 of *KIR3DL2* and 43 of *KIR3DL3*. We also identified 13 novel alleles for *KIR3DL1/S1*, 13 for *KIR3DL2* and 18 for *KIR3DL3* genes. The validation of these novel alleles is underway. Thus, the total numbers of alleles identified in the workshop samples were 46 for *KIR3DL1/S1*, 51 for *KIR3DL2* and 61 for *KIR3DL3* (Table 2), and these encode 37, 40 and 44 distinct KIR allotypes respectively (Table 2). Considering the modest sample sizes analyzed compared with *HLA* (more than 30 million to date [51]), this suggests that there are many more alleles remaining to be discovered and that the extent of *KIR* polymorphism identified in human populations could ultimately equal or exceed the extent of *HLA* polymorphism.

The allele frequencies of KIR receptors having three immunoglobulin (Ig)-like domains namely; *KIR3DL1/S1*, *KIR3DL2*, and *KIR3DL3* as well as the duplication/deletion polymorphism of *KIR3DL1/S1* detected in the 10 populations analyzed are given in Figures 1 and 2, respectively. These frequencies are deposited in the allele frequency net database (AFND) database (<http://www.allelefrequencys.net/default.asp>). Data were examined at the polypeptide sequence resolution, which is equivalent to the first three digits in the allele name, as described in IPD/KIR Database (<https://www.ebi.ac.uk/ipd/kir/>). The frequencies range from 0.1% to 48.7% for the various alleles of *KIR3DL1/S1* (Figure 1A), 0.1% to 61.7% for *KIR3DL2* (Figure 1B) and 0.1% to 33% for *KIR3DL3* (Figure 1C) in total across all populations. The number of those alleles classified as rare (those with a frequency of <1% in any given population) was 31 for *KIR3DL1/S1* (67.4%), 38 for *KIR3DL2* (74.5%), and 38 for *KIR3DL3* (62.3%). Thus, both common and rare alleles contributed substantially to the rich worldwide diversity of *KIR*. In addition to allelic variation, deletions and duplications of the entire *KIR3DL1/S1* gene were also observed (Figure 2). The highest frequency of deletions and duplications were observed in the Papuan population (13.5% and 8.4%, respectively). Meanwhile, no deletions and/or duplications were observed for *KIR3DL2* (except for *KIR3DL1/2v*, a fusion gene derived from *KIR3DL1* and *KIR3DL2*) [52].

Haplotypic diversity of *KIR3DL1/S1*, *KIR3DL2* and *KIR3DL3* genes

Specific *KIR* alleles and haplotypes are associated with better education of NK cells and/or control of specific pathogens [14, 53]. Diversity in *KIR* haplotypes may therefore contribute to improved population survival. To estimate the extent of haplotype diversity we analyzed the five populations that were genotyped for *KIR3DL3*, *KIR3DL1/S1* and *KIR3DL2*; European American, Ugandan, Papuan, Egyptian and Spanish (Table 2). *KIR3DL3* is located in the segment of the *KIR* region oriented towards the centromere of chromosome 19, and *KIR3DL1/S1* and *KIR3DL2* in the telomere oriented segment [4]. Since, the centromeric and telomeric *KIR* genes are separated by a region that contain a recombination hotspot [54, 55], we analyzed both full and telomeric-only haplotypes. We observed 503 distinct population-specific *KIR3DL3*~*KIR3DL1/S1*~*KIR3DL2* haplotypes and 158 distinct population-specific *KIR3DL1/S1*~*KIR3DL2* haplotypes. Additionally, we found six shared haplotypes, five of which, *3DL1*001*~*3DL2*001*, *3DL1*005*~*3DL2*010*, *3DS1*013*~*3DL2*007*, *3DL1*015*~*3DL2*002*, and *3DL3*003*~*3DS1*013*~*3DL2*007*

were present in all five populations (Table 3), and one (*3DL3*002~3DS1*013~3DL2*007*) was present in all except the Egyptian population (Table 3).

Our analysis of allelic variation in *KIR3DL3~KIR3DL1/S1~KIR3DL2* haplotypes revealed 234 distinct haplotypes in European Americans, 191 in Ugandans, 35 in Papua New Guineans, 95 in Egyptians, and 86 in the Spanish population (Table 2). The top ten most frequent *KIR3DL3~KIR3DL1/S1~KIR3DL2* haplotypes are listed in Table 2. Limiting to *KIR3DL1/S1~KIR3DL2* haplotypes, we identified 66 distinct haplotypes in European Americans, 81 in Ugandans, 16 in Papuans, 40 in Egyptians, and 24 in the Spanish population (Table 4). The top 10 most frequent *KIR3DL1/S1~KIR3DL2* haplotypes in each population are listed in Table 4.

***KIR3DL2* single nucleotide variations in exons 4 and 5**

To achieve a high-depth analysis in an extremely large sample size, we focused on exons 4 and 5 from *KIR3DL2*, which encode for the extracellular D1 and D2 domains of the *KIR3DL2* molecule, which are most likely to contact the HLA ligand directly [56]. We targeted 642,105 individuals from 35 populations and examined single nucleotide variations. We observed SNP variation in 78.5% (467 of 595) of all nucleotides that comprise these two exons. Among the observed single nucleotide substitutions, 67.4% (315 of 467) are nonsynonymous, and the reminders encode for either synonymous (31.3%) or premature stop codons (1.3%) (Table 5). Almost half of these nucleotide variations were observed in more than one individual, and the remainder in a single individual each (singletons). As expected, the number of these singletons increases with sample size (Supplementary Figure S1). Out of 375 *KIR3DL2* allelic variants identified in this study, 275 were population-specific and 221 were found in the German population, which is the population with the largest sample size.

***KIR* diversity in IHIW cell lines**

Data from a total of 19 IHIW cell lines from populations including European, black southern African, Warao Amerindian and Chinese were submitted for analysis. Different subsets of genes were investigated for each sample, resulting in the definition of 105 allele types in total, including 45 distinct alleles. The use of long read sequencing allowed the resolution of previous phase ambiguity over the large intron 5/6 (>5 Kbp) in *KIR3DL3*. In addition, novel *KIR3DL3* and *KIR2DL1* alleles were characterized in the cell lines AKIBA and SPO010, respectively, correcting previous allele typing [57]. Further characterization of a broader panel of IHIW cell lines using SMRT DNA sequencing is ongoing, helping to maintain the functionality of this valuable resource.

Future directions

The 17th IHIW *KIR* component has effectively applied the IHIW paradigm as a model for studying global *KIR* allelic diversity. Collaboration and multi-centric efforts were essential both to encourage the adoption of high-resolution *KIR* genotyping, and to generate *KIR* allelic data in an unprecedented scale from diverse ancestries. These data will be the basis of a more thorough examination of the *KIR* diversity in order to improve our understanding of *KIR* in human health and disease, as well as to provide a resource for immunogenetic

databases for future research. The *KIR* allelic data gathered in this project represents the most comprehensive summary of global *KIR3DL1/S1*, *KIR3DL3* and *KIR3DL2* allelic diversity to date and provides an increased understanding of *KIR* allelic polymorphism and *KIR* evolution. The intention of the organizers is to continue this work during the 18th IHIW that will be held in Amsterdam in 2021, with the hope that more laboratories will adopt *KIR* allelic genotyping approaches and that a greater number of populations will be analyzed for all *KIR* genes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We wish to thank all participants in this project, those who contributed to discussions during the project meeting in Asilomar, and the organizers of the 17th IHIW. Thanks to Illumina for supplying the sequencing and capture reagents, and Kapa Biosystems for supplying some of the library preparation reagents. National Institutes of Health (NIH) grant U19NS095774 (JAH, PJN, JRO, MKM), NIH RO1 AI17892 (PP) and NIH P01 CA111412 (SGEM) supported this work. This project has received funding for *KIR* genotyping of the Ugandan samples from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 695551); and Wellcome programme grants and enhancement awards related to the collection and study of Ugandan cohort (MR/L020041/1, 094073/Z/10/Z, 094073/Z/10/B). We are grateful to the participants in the Papua New Guinea Highlands for taking part in this study and for Dr. Willie Pomat and Dr. George Koki from the PNG Institute for Medical Research for their assistance in collecting samples associated with the Papua New Guinea cohort, and AJM was supported by a Wellcome Trust Fellowship with reference 106289/Z/14/Z. We also thank Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Science Without Borders program award, Fundação Araucária, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) that supported the genotyping of the Brazilian samples.

References

- [1]. Liu WR, Kim J, Nwankwo C, Ashworth LK, Arm JP: Genomic organization of the human leukocyte immunoglobulin-like receptors within the leukocyte receptor complex on chromosome 19q13.4. *Immunogenetics* 2000;51:659. [PubMed: 10941837]
- [2]. Wende H, Colonna M, Ziegler A, Volz A: Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. *Mamm Genome* 1999;10:154. [PubMed: 9922396]
- [3]. Misra MK, Damotte V, Hollenbach JA: The immunogenetics of neurological disease. *Immunology* 2018;153:399. [PubMed: 29159928]
- [4]. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D et al. : Plasticity in the organization and sequences of human *KIR/ILT* gene families. *Proc Natl Acad Sci U S A* 2000;97:4778. [PubMed: 10781084]
- [5]. Colonna M, Moretta A, Vely F, Vivier E: A high-resolution view of NK-cell receptors: structure and function. *Immunol Today* 2000;21:428. [PubMed: 11012243]
- [6]. Bjorkstrom NK, Beziat V, Cichocki F, Liu LL, Levine J, Larsson S et al. : CD8 T cells express randomly selected *KIRs* with distinct specificities compared with NK cells. *Blood* 2012;120:3455. [PubMed: 22968455]
- [7]. Robinson J, Mistry K, McWilliam H, Lopez R, Marsh SG: IPD--the Immuno Polymorphism Database. *Nucleic Acids Res* 2010;38:D863. [PubMed: 19875415]
- [8]. Parham P, Norman PJ, Abi-Rached L, Guethlein LA: Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. *Philos Trans R Soc Lond B Biol Sci* 2012;367:800. [PubMed: 22312047]
- [9]. Knapp S, Warshaw U, Hegazy D, Brackenbury L, Guha IN, Fowell A et al. : Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. *Hepatology* 2010;51:1168. [PubMed: 20077564]

- [10]. Carrillo-Bustamante P, Kesmir C, de Boer RJ: Virus encoded MHC-like decoys diversify the inhibitory KIR repertoire. *PLoS Comput Biol* 2013;9:e1003264. [PubMed: 24130473]
- [11]. Hollenbach JA, Ladner MB, Saeteurn K, Taylor KD, Mei L, Haritunians T et al. : Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. *Immunogenetics* 2009;61:663. [PubMed: 19789864]
- [12]. Augusto DG, Lobo-Alves SC, Melo MF, Pereira NF, Petzl-Erler ML: Activating KIR and HLA Bw4 ligands are associated to decreased susceptibility to pemphigus foliaceus, an autoimmune blistering skin disease. *PLoS One* 2012;7:e39991. [PubMed: 22768326]
- [13]. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F et al. : Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. *Nat Genet* 2007;39:733. [PubMed: 17496894]
- [14]. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J et al. : HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. *Science* 2004;305:872. [PubMed: 15297676]
- [15]. Misra MK, Prakash S, Moulik NR, Kumar A, Agrawal S: Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians. *Hum Immunol* 2016;77:41. [PubMed: 26472014]
- [16]. Boudreau JE, Giglio F, Gooley TA, Stevenson PA, Le Luduec JB, Shaffer BC et al. : KIR3DL1/HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. *J Clin Oncol* 2017;35:2268. [PubMed: 28520526]
- [17]. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CW, Carrington M, Trowsdale J et al. : Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. *J Exp Med* 2004;200:957. [PubMed: 15477349]
- [18]. Nakimuli A, Chazara O, Hiby SE, Farrell L, Tukwasibwe S, Jayaraman J et al. : A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia. *Proc Natl Acad Sci U S A* 2015;112:845. [PubMed: 25561558]
- [19]. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT et al. : Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. *Blood* 2009;113:726. [PubMed: 18945962]
- [20]. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SG et al. : Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. *J Immunol* 2014;192:4592. [PubMed: 24748496]
- [21]. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. : Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* 2002;295:2097. [PubMed: 11896281]
- [22]. Kunert K, Seiler M, Mashreghi MF, Klippert K, Schonemann C, Neumann K et al. : KIR/HLA ligand incompatibility in kidney transplantation. *Transplantation* 2007;84:1527. [PubMed: 18091530]
- [23]. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL et al. : Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. *Nucleic Acids Res* 2015;43:D784. [PubMed: 25414323]
- [24]. Takeshita LY, Gonzalez-Galarza FF, dos Santos EJ, Maia MH, Rahman MM, Zain SM et al. : A database for curating the associations between killer cell immunoglobulin-like receptors and diseases in worldwide populations. *Database (Oxford)* 2013;2013:bat021. [PubMed: 23584834]
- [25]. Middleton D, Gonzelez F: The extensive polymorphism of KIR genes. *Immunology* 2010;129:8. [PubMed: 20028428]
- [26]. Barten R, Torkar M, Haude A, Trowsdale J, Wilson MJ: Divergent and convergent evolution of NK-cell receptors. *Trends Immunol* 2001;22:52. [PubMed: 11286693]
- [27]. Middleton D, Meenagh A, Gourraud PA: KIR haplotype content at the allele level in 77 Northern Irish families. *Immunogenetics* 2007;59:145. [PubMed: 17200871]
- [28]. Gendzekhadze K, Norman PJ, Abi-Rached L, Graef T, Moesta AK, Layrisse Z et al. : Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. *Proc Natl Acad Sci U S A* 2009;106:18692. [PubMed: 19837691]

- [29]. Vierra-Green C, Roe D, Hou L, Hurley CK, Rajalingam R, Reed E et al. : Allele-level haplotype frequencies and pairwise linkage disequilibrium for 14 KIR loci in 506 European-American individuals. *PLoS One* 2012;7:e47491. [PubMed: 23139747]
- [30]. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Guethlein LA, Hilton HG, Pando MJ et al. : Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. *PLoS Genet* 2013;9:e1003938. [PubMed: 24204327]
- [31]. Nemat-Gorgani N, Edinur HA, Hollenbach JA, Traherne JA, Dunn PP, Chambers GK et al. : KIR diversity in Maori and Polynesians: populations in which HLA-B is not a significant KIR ligand. *Immunogenetics* 2014;66:597. [PubMed: 25139336]
- [32]. Nemat-Gorgani N, Hilton HG, Henn BM, Lin M, Gignoux CR, Myrick JW et al. : Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2(+) HLA-C in Two Indigenous Human Populations in Southern Africa. *J Immunol* 2018;200:2640. [PubMed: 29549179]
- [33]. Hollenbach JA, Meenagh A, Sleator C, Alaez C, Bengoche M, Canossi A et al. : Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the 15th International Histocompatibility Workshop: worldwide variation in the KIR loci and further evidence for the coevolution of KIR and HLA. *Tissue Antigens* 2010;76:9. [PubMed: 20331834]
- [34]. Hollenbach JA, Augusto DG, Alaez C, Bubnova L, Fae I, Fischer G et al. : 16(th) IHIW: population global distribution of killer immunoglobulin-like receptor (KIR) and ligands. *Int J Immunogenet* 2013;40:39. [PubMed: 23280119]
- [35]. Single RM, Martin MP, Gao X, Meyer D, Yeager M, Kidd JR et al. : Global diversity and evidence for coevolution of KIR and HLA. *Nat Genet* 2007;39:1114. [PubMed: 17694058]
- [36]. Augusto DG, Petzl-Erler ML: KIR and HLA under pressure: evidences of coevolution across worldwide populations. *Hum Genet* 2015;134:929. [PubMed: 26099314]
- [37]. Contreras G, Alaez C, Murguia A, Garcia D, Flores H, Gorodezky C: Distribution of the killer cell immunoglobulin-like receptors in Mexican Mestizos. *Tissue Antigens* 2007;69 Suppl 1:125. [PubMed: 17445185]
- [38]. Parham P, Norman PJ, Abi-Rached L, Guethlein LA: Variable NK cell receptors exemplified by human KIR3DL1/S1. *J Immunol* 2011;187:11. [PubMed: 21690332]
- [39]. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Marin WM, Norberg SJ, Ashouri E et al. : Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing. *Am J Hum Genet* 2016;99:375. [PubMed: 27486779]
- [40]. Nakimuli A, Chazara O, Farrell L, Hiby SE, Tukwasibwe S, Knee O et al. : Killer cell immunoglobulin-like receptor (KIR) genes and their HLA-C ligands in a Ugandan population. *Immunogenetics* 2013;65:765. [PubMed: 23974321]
- [41]. Elfishawi SM, Mossallam GI, El-Fattah RA, El-Haddad A, Kamel AM: The effect of killer cell immunoglobulin-like receptor genotype on outcome of hematopoietic stem cell transplantation from matched sibling. *Hum Immunol* 2017;78:684. [PubMed: 28993188]
- [42]. Vilches C, Castano J, Gomez-Lozano N, Estefania E: Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. *Tissue Antigens* 2007;70:415. [PubMed: 17854430]
- [43]. Creary LE, Mallempati KC, Gangavarapu S, Caillier SJ, Oksenberg JR, Fernandez-Vina MA: Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis. *Mult Scler* 2018;1352458518770019. [PubMed: 29683085]
- [44]. Bergstrom A, Oppenheimer SJ, Mentzer AJ, Auckland K, Robson K, Attenborough R et al. : A Neolithic expansion, but strong genetic structure, in the independent history of New Guinea. *Science* 2017;357:1160. [PubMed: 28912245]
- [45]. Augusto DG, Amorim LM, Farias TD, Petzl-Erler ML: KIR and HLA genotyping of Japanese descendants from Curitiba, a city of predominantly European ancestry from Southern Brazil. *Hum Immunol* 2016;77:336. [PubMed: 26805458]

- [46]. Augusto DG, Piovezan BZ, Tsuneto LT, Callegari-Jacques SM, Petzl-Erler ML: KIR gene content in amerindians indicates influence of demographic factors. *PLoS One* 2013;8:e56755. [PubMed: 23451080]
- [47]. Augusto DG, Zehnder-Alves L, Pincerati MR, Martin MP, Carrington M, Petzl-Erler ML: Diversity of the KIR gene cluster in an urban Brazilian population. *Immunogenetics* 2012;64:143. [PubMed: 21850526]
- [48]. Lange V, Bohme I, Hofmann J, Lang K, Sauter J, Schone B et al. : Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing. *BMC Genomics* 2014;15:63. [PubMed: 24460756]
- [49]. Ihaka R, Gentleman R: R: A language for data analysis and graphics. *Journal of Computational and Graphical Statistics*, 1996;5:299.
- [50]. Sinnwell J, Schaid D: haplo.stats: Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous. R package version 1.7.1. 2015.
- [51]. Robinson J, Guethlein LA, Cereb N, Yang SY, Norman PJ, Marsh SGE et al. : Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. *PLoS Genet* 2017;13:e1006862. [PubMed: 28650991]
- [52]. Norman PJ, Abi-Rached L, Gendzekhadze K, Hammond JA, Moesta AK, Sharma D et al. : Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes. *Genome Res* 2009;19:757. [PubMed: 19411600]
- [53]. Boudreau JE, Hsu KC: Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. *Trends Immunol* 2018;39:222. [PubMed: 29397297]
- [54]. Vendelbosch S, de Boer M, van Leeuwen K, Pourfarzad F, Geissler J, van den Berg TK et al. : Novel insights in the genomic organization and hotspots of recombination in the human KIR locus through analysis of intergenic regions. *Genes Immun* 2015;16:103. [PubMed: 25503311]
- [55]. Norman PJ, Cook MA, Carey BS, Carrington CV, Verity DH, Hameed K et al. : SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex. *Immunogenetics* 2004;56:225. [PubMed: 15185041]
- [56]. Vivian JP, Duncan RC, Berry R, O'Connor GM, Reid HH, Beddoe T et al. : Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. *Nature* 2011;479:401. [PubMed: 22020283]
- [57]. Bultitude WP, Gymer AW, Robinson J, Mayor NP, Marsh SGE: The novel KIR2DL1 allele, KIR2DL1*037, defined in the cell line SPO010 (IHW9036). *HLA* 2018;91:547. [PubMed: 29660261]




Figure 1: Allele frequency distribution in workshop populations for KIR receptors having three immunoglobulin (Ig)-like domains.

Figure 1A: *KIR3DL1/S1* allele frequency distribution in workshop populations. Figure 1B: *KIR3DL2* allele frequency distribution in workshop populations. Figure 1C: *KIR3DL3* allele frequency distribution in workshop populations.




Figure 2:
KIR3DL1/S1 structural variations in workshop populations.

Table 1:

Details of *KIR* allele-level sequencing of workshop populations, including sample size, *KIR* genes, *KIR* typing method, sample contributor and sequencing location

Population	N	Genes	Method	Sample contributor	[§] Sequencing
Uganda	174	<i>KIR3DL1/S1</i> , <i>KIR3DL2</i> and <i>KIR3DL3</i>	NGS	Traherne/Moffett	Local
Egypt	136	<i>KIR3DL1/S1</i> , <i>KIR3DL2</i> and <i>KIR3DL3</i>	NGS	Elfishawi	Stanford
European American	378	<i>KIR3DL1/S1</i> , <i>KIR3DL2</i> and <i>KIR3DL3</i>	NGS	Hollenbach/Oksenberg	Stanford
Papua New Guinea	185	<i>KIR3DL1/S1</i> , <i>KIR3DL2</i> and <i>KIR3DL3</i>	NGS	Mentzer/Oppenheimer	Stanford
Spain	153	<i>KIR3DL1/S1</i> , <i>KIR3DL2</i> and <i>KIR3DL3</i>	NGS	GETHIT [#]	Stanford
Curitiba	42	<i>KIR3DL2</i>	Sanger	Augusto/Petzl-Erler	Local
Kaingang	30	<i>KIR3DL2</i>	Sanger	Augusto/Petzl-Erler	Local
Guarani	49	<i>KIR3DL2</i>	Sanger	Augusto/Petzl-Erler	Local
Japanese-Brazilian	22	<i>KIR3DL2</i>	Sanger	Augusto/Petzl-Erler	Local
Mexican Mestizos	100	<i>KIR3DL1S1</i>	Sanger	Gorodezky	Local
Germany	564253	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Poland	6509	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Kosovo	649	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Serbia	857	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Croatia	1947	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Brazil	381	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Syria	554	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Bosnia-Herzegovina	992	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Sri Lanka	1809	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Austria	1374	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Czech Republic	620	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Kazakhstan	1701	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Spain	1053	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
France	865	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
India	393	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
USA	903	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Vietnam	546	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Greece	2695	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Hungary	833	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Romania	1425	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Afghanistan	541	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Great Britain	755	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Burundi	398	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Albania	469	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local
Lebanon	437	<i>KIR3DL2</i> exons 4 and 5	NGS	DKMS	Local

Population	N	Genes	Method	Sample contributor	[§] Sequencing
Other	8326	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Russia	5288	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Switzerland	405	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Portugal	1450	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Turkey	26119	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Netherlands	981	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Iran	1059	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Italy	4416	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Morocco	449	KIR3DL2 exons 4 and 5	NGS	DKMS	Local
Ukraine	653	KIR3DL2 exons 4 and 5	NGS	DKMS	Local

[#]**GETHIT** means for Spanish Working Group in Histocompatibility and Transplant Immunology study;

[§]**Local sequencing** means *KIR* genotyping was performed by the participant's lab either using a NGS exome capture method [38] for *KIR* genes containing three Ig receptors (Traherne/Moffett lab) or Sanger sequencing for *KIR3DL1S1* (Gorodezky lab) and *KIR3DL2* (Augusto/Petzi-Erler) or an in-house developed NGS short amplicon approach for *KIR3DL2* (DKMS lab). For **Stanford Sequencing**, *KIR* genotyping was performed at Stanford using a NGS exome capture method [38].

Table 2:

Allelic variations of one centromeric (*KIR3DL3*) and two telomeric (*KIR3DL1/S1* and *KIR3DL2*) genes diversifies *KIR* haplotypes in European American, Ugandan, Papuan, Egyptian and Spanish populations

Population	Centromeric	Telomeric		Frequency
	<i>KIR3DL3</i>	<i>KIR3DL1/S1</i>	<i>KIR3DL2</i>	
European American [‡] (Total observed 234)	*003	<i>S1*013</i>	*007	0.051
	*001	<i>S1*013</i>	*007	0.043
	*001	<i>L1*004</i>	*005	0.035
	*001	<i>L1*002</i>	*002	0.028
	*002	<i>L1*001</i>	*001	0.028
	*002	<i>L1*005</i>	*001	0.027
	*003	<i>L1*002</i>	*002	0.026
	*013	<i>L1*001</i>	*001	0.020
	*013	<i>S1*013</i>	*007	0.020
	*001	<i>L1*001</i>	*001	0.018
Ugandan [‡] (Total observed 191)	*005	<i>L1*001</i>	*001	0.049
	*002	<i>L1*015</i>	*001	0.031
	*014	<i>L1*031</i>	*001	0.028
	*010	<i>L1*017</i>	*023	0.026
	*014	<i>L1*018</i>	*001	0.023
	*011	<i>L1*018</i>	*001	0.020
	*022	NEG	*006	0.020
	*009	<i>L1*022</i>	*001	0.019
	*004	<i>L1*059^a</i>	-	0.017
	*003	<i>L1*007</i>	*008	0.017
Papuan [‡] (Total observed 35)	*002	<i>S1*013</i>	*007	0.165
	*014	<i>S1*013</i>	*007	0.142
	*014	NEG	*007	0.100
	*003	<i>S1*013</i>	*007	0.100
	*014	<i>L1*017</i>	*002	0.075
	*002	<i>L1*017</i>	*002	0.066
	*003	<i>L1*017</i>	*002	0.060
	*009	<i>S1*013</i>	*007	0.051
	*013	<i>L1*005</i>	*010	0.047
	*013	<i>L1*017</i>	*002	0.028
Egyptian [‡] (Total observed 95)	*003	<i>L1*001</i>	*001	0.045
	*009	<i>L1*001</i>	*001	0.034
	*003	<i>S1*013</i>	*007	0.034
	*003	<i>L1*002</i>	*002	0.027

	Centromeric	Telomeric		
Population	<i>KIR3DL3</i>	<i>KIR3DL1/S1</i>	<i>KIR3DL2</i>	Frequency
	*003	<i>L1*007</i>	*008	0.027
	*001	<i>L1*020</i>	*009	0.027
	*014	<i>S1*013</i>	*007	0.027
	*013	<i>L1*001</i>	*001	0.020
	*027	<i>L1*001</i>	*001	0.020
	*015	<i>L1*002</i>	*002	0.020
Spanish [‡] (Total observed 86)	*003	<i>L1*002</i>	*002	0.055
	*002	<i>L1*005</i>	*001	0.050
	*001	<i>L1*001</i>	*001	0.047
	*001	<i>L1*004</i>	*005	0.047
	*003	<i>S1*013</i>	*007	0.046
	*009	<i>S1*013</i>	*007	0.040
	*002	<i>S1*013</i>	*007	0.040
	*002	<i>L1*004</i>	*003	0.035
	*002	<i>L1*001</i>	*001	0.031
*001	<i>L1*015</i>	*002	0.026	
# Total Alleles	61	46	51	
\$ Total Allotypes	44	37	40	

[‡]The number of distinct haplotypes identified by analyzing one centromeric (*KIR3DL3*) and two telomeric (*KIR3DL1/S1* and *KIR3DL2*) genes;

Number of distinct alleles (including novel alleles);

\$ Number of distinct allotypes (including novel allotypes);

^a*L1*059* is an allele of *KIR3DL1/2v*, a fusion gene derived from *KIR3DL1* and *KIR3DL2*.

Table 3:

A summary of six haplotypes shared across five populations analyzed

A. Haplotypes of <i>KIR3DL3</i>, <i>KIR3DL1/S1</i> and <i>KIR3DL2</i>							
Centromeric	Telomeric		Haplotype Frequency				
<i>KIR3DL3</i>	<i>KIR3DL1/S1</i>	<i>KIR3DL2</i>	European American	Spanish	Egyptian	Ugandan	Papuan
<i>*003</i>	<i>S1*013</i>	<i>*007</i>	0.051	0.046	0.034	0.003	0.100
<i>*002</i>	<i>S1*013</i>	<i>*007</i>	0.016	0.040	-	0.003	0.165
B. Haplotypes of <i>KIR3DL1/S1</i> and <i>KIR3DL2</i>							
Telomeric		Haplotype Frequency					
<i>KIR3DL1/S1</i>	<i>KIR3DL2</i>	European American	Spanish	Egyptian	Ugandan	Papuan	
<i>L1*001</i>	<i>*001</i>	0.115	0.124	0.174	0.072	0.005	
<i>L1*005</i>	<i>*010</i>	0.017	0.019	0.050	0.011	0.100	
<i>S1*013</i>	<i>*007</i>	0.189	0.138	0.116	0.020	0.481	
<i>L1*015</i>	<i>*002</i>	0.071	0.071	0.012	0.011	0.014	

Table 4:

The 10 most frequent *KIR3DL1/S1* and *KIR3DL2* haplotypes in European American, Ugandan, Papuan, Egyptian and Spanish populations

Population	Telomeric		Frequency
	<i>KIR3DL1/S1</i>	<i>KIR3DL2</i>	
European American [‡] (Total observed 66)	<i>S1*013</i>	*007	0.189
	<i>L1*001</i>	*001	0.115
	<i>L1*002</i>	*002	0.112
	<i>L1*005</i>	*001	0.079
	<i>L1*015</i>	*002	0.071
	<i>L1*004</i>	*003	0.071
	<i>L1*004</i>	*005	0.063
	<i>L1*008</i>	*009	0.040
	<i>L1*001</i>	*011	0.028
	<i>L1*020</i>	*009	0.027
Ugandan [‡] (Total observed 81)	<i>L1*015</i>	*001	0.092
	<i>L1*031</i>	*001	0.077
	<i>L1*001</i>	*001	0.072
	<i>L1*004</i>	*003	0.052
	<i>L1*059^a</i>	-	0.046
	<i>L1*018</i>	*001	0.041
	<i>L1 NEG</i>	*019	0.040
	<i>L1*022</i>	*001	0.036
	<i>L1*015</i>	*013	0.033
	<i>L1 NEG</i>	*006	0.032
Papuan [‡] (Total observed 16)	<i>S1*013</i>	*007	0.481
	<i>L1*017</i>	*002	0.243
	<i>L1 NEG</i>	*007	0.124
	<i>L1*005</i>	*010	0.100
	<i>L1*015</i>	*002	0.014
	<i>L1*001</i>	*001	0.005
	<i>L1*005</i>	*001	0.005
	<i>S1*013</i>	*010	0.005
	<i>L1 NEG</i>	*010	0.005
	<i>L1 NEG</i>	*070	0.005
Egyptian [‡] (Total observed 40)	<i>L1*001</i>	*001	0.174
	<i>S1*013</i>	*007	0.116
	<i>L1*002</i>	*002	0.093
	<i>L1*004</i>	*005	0.070

Population	Telomeric		Frequency
	<i>KIR3DL1/S1</i>	<i>KIR3DL2</i>	
	<i>L1*004</i>	<i>*003</i>	0.052
	<i>L1*005</i>	<i>*010</i>	0.050
	<i>L1*008</i>	<i>*009</i>	0.047
	<i>S1*013</i>	<i>*006</i>	0.041
	<i>L1*014</i>	<i>*032</i>	0.035
	<i>L1*005</i>	<i>*001</i>	0.031
Spanish [‡] (Total observed 24)	<i>L1*005</i>	<i>*001</i>	0.138
	<i>S1*013</i>	<i>*007</i>	0.138
	<i>L1*001</i>	<i>*001</i>	0.124
	<i>L1*002</i>	<i>*002</i>	0.100
	<i>L1*004</i>	<i>*005</i>	0.100
	<i>L1*004</i>	<i>*003</i>	0.095
	<i>L1*015</i>	<i>*002</i>	0.071
	<i>L1*007</i>	<i>*008</i>	0.048
	<i>L1*001</i>	<i>*011</i>	0.038
<i>L1*009</i>	<i>*011</i>	0.024	

[‡]The number of distinct haplotypes identified by analyzing two telomeric genes (*KIR3DL1/S1* and *KIR3DL2*);

^a*L1*059* is an allele of *KIR3DL1/2v*, a fusion gene derived from *KIR3DL1* and *KIR3DL2*.

Table 5:

KIR3DL2 variation in exons 4 and 5 (D1 and D2 domains) among 642,105 individuals from 35 populations

<i>KIR3DL2</i> variation	Count
Allelic variation	
1 nucleotide change	288
2 nucleotide changes	82
3 nucleotide changes	5
Sum of all allelic variants	375
Variant description	
Single nucleotide polymorphism	467
Synonymous substitutions	146
Non-synonymous substitutions	315
Premature stop codon	6
Total number of nucleotide sites	595
Number of Amino Acid changes	Codon
0	23
1	77
2	66
3	24
4	7
5	1
Polypeptide sites	199